期刊文献+

白血病细胞来源胞外体的生物学特性及其致敏DC的抗白血病效应 被引量:1

Biological properties of leukemia cell-derived exosome and anti-leukemia effects of its sensitized DCs
原文传递
导出
摘要 目的:探索白血病细胞来源的胞外体(leukemia cell-derived exosome,LEX)的生物学特性及其致敏DC的抗白血病免疫效应。方法:超速离心分离纯化BCR-ABL阳性的白血病K562细胞来源的胞外体(LEXK562),采用免疫电镜及Westernblotting检测LEXK562中热激蛋白70(heat shock protein 70,HSP70)及BCR-ABL的表达,采用激光扫描共聚焦显微镜及流式细胞术检测LEXK562靶向结合DC的动力学,采用LDH释放法以及小鼠模型体内实验检测LEX及其致敏DC的抗白血病免疫效应。结果:与其他细胞来源的胞外体相似,K562细胞来源的胞外体LEXK562为直径50~100 nm的囊状结构,且表达K562细胞特异性的BCR-ABL和HSP70分子。LEXK562在体外可靶向结合DC,3~4 h到达高峰,并能在DC中稳定存在72 h以上。LEXK562致敏DC(DC/LEXK562)诱导的细胞毒性T淋巴细胞(cytotoxic T lymphocyte,CTL)可有效杀伤K562靶细胞,效靶比为50∶1时,其杀伤活性显著高于LEXK562诱导的CTL[(68.6±5.7)%vs(22.5±2.9)%,P<0.01];体内实验进一步证实,白血病L1210细胞来源的胞外体(LEXL1210)免疫后小鼠接种L1210细胞的成瘤率明显高于LEXL1210致敏DC(DC/LEXL1210)免疫小鼠的成瘤率[(54.17±8.33)%vs(16.67±4.18)%,P<0.05]。结论:LEX表达白血病细胞相关抗原,LEX体外可靶向结合DC,其致敏的DC能诱导更强的抗白血病免疫效应。 Objective:To explore the biological properties of leukemia cell-derived exosomes (LEXs) and the anti-leukemia immunological effect of LEX-sensitized dendritic cells (DCs). Methods: LEX from BCR-ABL positive leukemia K562 cells was separated and purified by ultracentrifugation. The expressions of heat shock protein 70 (HSP70) and BCR-ABL were investigated by immuno-electron microscopy and Western blotting. The kinetics of LEXK562 targeted binding to DCs was examined by laser scanning confocal microscopy and flow cytometry. The anti-leukemia immunological effect of LEX and its sensitized DCs was explored by LDH release assay and in vivo mouse model studies. Results: K562 cell-derived exosomes (LEXK562) had cystic structures between 50 and 100 nm diameter as the other cell-derived exosomes, and expressed K562 cell specific proteins, HSP70 and BCR-ABL. LEXK562 could target and bind DCs in vitro, and reached a plateau after 3 to 4 h of co-culturing. LEXK562 uptaken in DCs was quite stable for over 72 h. Cytotoxic T lymphocytes (CTLs) induced by LEXK562-sensitized DCs (DC/LEXK562) could effectively kill K562 target cells, and their cytotoxicity was significantly higher than that of CTLs induced by LEXK562 (/[68.6±5.7/]% vs /[22.5±2.9/]%, P〈0.01) at an effector to target ratio of 50∶1. Furthermore, the in vivo study demonstrated that the incidence of tumor in mice incubation with leukemia L1210 cells after being immunized with L1210-derived exosomes (LEXL1210) was significantly higher than that of LEXL1210-sensitized DCs (/[54.17±8.33/]% vs /[16.67±4.18/]%, P〈0.05). Conclusion: LEX expresses antigens associated with leukemia cells and can target bind DCs in vitro. LEX-sensitized DCs can induce a stronger anti-leukemia immunological effect.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2013年第1期13-19,共7页 Chinese Journal of Cancer Biotherapy
基金 国家自然科学基金资助项目(No.81070432) 上海市浦江人才计划资助项目(No.08PJ1407600)~~
关键词 白血病细胞 K562细胞 L1210细胞 胞外体 树突状细胞 免疫治疗 leukemia cell K562 cell L1210 cell exosome dendritic cell immunotherapy
  • 相关文献

参考文献1

二级参考文献7

  • 1卜宁,孙秉中,李奇灵,于月成,张涛,王一苇,乔庆大.K562细胞分泌的exosome的免疫电镜研究[J].第四军医大学学报,2005,26(5):401-403. 被引量:4
  • 2ZITVOGEL L, REGNAULT A, LOZIER A, et al.Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes[J].Nat Med, 1998: 4:594-600.
  • 3WOLFERS J, LOZIER A, RAPOSO G, et al.Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming [J]. Nat Med, 2001, 7:297-303.
  • 4ANDRE F, SCHARTZ N E C, MOVASSAGH M,et al. Malignant effusions and immunogenic tumourderived exosomes[J]. Lancet, 2002, 360:295-305.
  • 5NESTLE F O, ALIJAGIC S, GILLIET M, et al.Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells [J]. Nat Med,1998, 4:328-332.
  • 6HENRY G L, ANITA M D, SANJAY P, et al. Production and characterization of clinical grade exosomes derived from dendritic cells [J]. J Immunological Methods, 2002, 270:211-226.
  • 7ALTIERI S L, KHAN A N, TOMASI T B. Exosomes from plasmacytoma cells as a tumor vaccine[J]. J Immunother, 2004, 27:282-288.

共引文献7

同被引文献4

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部